FDA
-
-
-
-
-
-
-
BioMarin drug trial meets one of two primary goals in rare disease study
-
-
-
-
-
-
-
BioMarin appoints Ian Clark as board chair, Richard Meier to retire
-
-
-
-
-
-
-
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
-
-
-
-
-
-
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $55 at H.C. Wainwright
-
-
-
-
-
-
-
Wolfe Research Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
-
-
-
-
-
-
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
-
-
-
-
-
-
-
Is Trump 2.0 good or bad for healthcare stocks?
-
325,447 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

